iron

Prothrombin Time Comes in Small (CLIA-Waived) Packages

...etic fields in the cocktail cause pre-incorporated iron particles in the strips reaction chamber to move. An endpoint is reached when the formation of a clot causes immobilization of these particles. The company says that the system includes one of the fastest coagulation meters available, with results av...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

...l, polyethyleneglycol, talc, titanium dioxide, red iron oxide, and yellow iron oxide. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Sitagliptin is a DPP-4 inhibitor, ...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

...l, polyethyleneglycol, talc, titanium dioxide, red iron oxide, and yellow iron oxide. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Sitagliptin is a DPP-4 inhibitor, ...

Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain

.... The research group placed miniscule particles of iron insidestem cells to act as cellular beacons detect...e research group, said thework also shows that the iron doesn't disrupt the normal functionof the stem cells. "This work is important because if a method of...

World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester

...this condition is theaccumulation of protein-bound iron in the lungs, a consequence ofrepeated bleeding in...ent anaemia is a combination ofcorticosteroids and iron supplement. Both chronic inflammation, and the presence of iron, releasedfollowing bleeding into th...

New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At Annual Digestive Disease Week Meeting

...t determinant ofbioavailability (eg, ketoconazole, iron salts, digoxin).Concomitant administration of esomeprazole may reduce the plasmalevels of atazanavir. Concomitant administration of esomeprazole may reduce the plasmaof atazanavir. NEXIUM should be used only for the conditions, dosages, andduration...

Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria

...ncluding haem oxygenase, bilirubinaemias etc.) and iron relatedtopics, and general porphyria. Diagnostics/therapies/clinicalissues, including drug porphyrinogenicity will also be covered. For further information, please contact: AMT: Prof. Sander Van Deventer, CSO Phone: +31 20 566 7394 Email: <a...

Vion Presents Data on Cloretazine (VNP40101M) at the 100th Annual Meeting of the American Association of Cancer Research (AACR)

...r #26 (section 7) entitled "Triapine(R) binds with iron andcauses S- phase arrest and activation of the apoptotic pathway inadvanced cancer patients" will be presented on Monday, April 16from 8 a.m. to 12 p.m. Vion Pharmaceuticals, Inc. is committed to extending the livesand improving the quality of life...

Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study

...shed using the 400 mg tablet to reduce exposure to iron Use of Gleevec tablets is contraindicated in patients withhypersensitivity to imatinib or to any other component of Gleevectablets Women of childbearing potential should be advised to avoidbecoming pregnant while taking Gleevec tablets and should b...

Advanced Magnetics Announces Positive Results from Two Additional Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement Therapeutic

...inical trials of ferumoxytol as anintravenous (IV) iron replacement therapeutic that are beingpresented to...es of ferumoxytol within one week or200 mg of oral iron daily for three weeks. This Phase III studydemonstrated a statistically significant achievement of a...

Advanced Magnetics Announces Presentation of Ferumoxytol Data at the National Kidney Foundation 2007 Spring Clinical Meetings

...r clinical studies of ferumoxytol as anintravenous iron replacement therapeutic will be presented duringth... the ferumoxytolgroup compared to that in the oral iron treatment group. Resultsfrom the second NDD-CKD study, protocol 62,745-7, which completedenrollment ...